TEMP CLONE Bleeding and Clotting Disorders
Upon completion of this session, you should be able to:
1. Apply case-based learning to the etiology, differentiation and management of bleeding disorders in patients with unexplained bleeding.
2. Develop a treatment/management plan for patients with hemophilia A and other rare bleeding disorders, including new and emerging recombinant products, in accordance with the most recent evidence-based recommendations.
3. Choose appropriate anticoagulant therapy based on disease specific recommendations for outpatient management.
4. Provide patient education regarding the FDA REMS guidelines for the use of rivaroxaban (Xarelto).
View technical requirements (opens in a new window).
View CME credit information (opens in a new window).
View disclosures and disclaimers (opens in a new window).
All materials herein are protected by copyright and are for the sole, personal use of the purchaser. No part of the written, oral, and broadcast production may be copied, duplicated, replicated or retransmitted without the prior permission of the applicable copyright owner.
The unauthorized reproduction or distribution of a copyrighted work is illegal. Criminal copyright infringement, including infringement without monetary gain, is investigated by the FBI and is punishable by up to five years in federal prison and a fine of $250,000.
David T Walsworth, MD, FAAFP, Associate Chair for Clinical Affairs; Associate Professor, Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan
- 1.00 AAFP prescribed